- Gupta N, Weber H, Moss S, Gaire-Patel K. Are antibiotic resistant “super bugs” a
real challenge to antimicrobial central venous catheter performance? AVA 2014.
- O’Grady NP, Alexander M, Burns LA, Dellinger P, Garland J, Heard SO et al Guidelines
for the Prevention of Intravascular Catheter-related Infections, 2011. The Centers for Disease
- SHEA Compendium
- Gorski LA, Hadaway L, Hagle M, Broadhurst D, Clare S. Infusion therapy standards of
practice. Journal of Infusion
Nursing. 8th Edition Revised 2021
- Pittiruti M, Hamilton H, BiffiR, MacFieJ, PertkiewiczM, Espen. ESPEN Guidelines on
Parenteral Nutrition: central venous
catheters (access, care, diagnosis and therapy of complications). Clinical nutrition.
- Loveday HP, Wilson JA, Pratt RJ, et al. epic3: national evidence-based guidelines for
infections in NHS hospitals in England. J Hosp Infect. 2014;86 Suppl 1:S1-70.
- Standards for infusion therapy. 4th ed. London: Royal College of Nursing; 2016.
- Kommission für Krankenhaushygiene und Infektionsprävention (RKI KRINKO). Prävention von
von Gefäßkathetern ausgehen. Bundesgesundheitsbl.
- Rosenbauer KA, Herzer JA. Surface morphology and tensile force at breaking point or
different kinds of intravenous catheters before and after usage. Scan Electron Microsc.
- Collins JL, Lutz RJ. In vitro Study of Simultaneous Infusion of Incompatible Drugs
in Multilumen Catheters. Heart & Lung. 1991; 20(3):271-7.
*Use a chlorhexidine/silver sulfadiazine or minocycline/rifampin -impregnated
CVC in patients whose catheter is expected to remain in place >5 days if, after successful
implementation of a comprehensive strategy to reduce rates of CLABSI, the CLABSI rate is not
**Use such catheters in the following instances: i. Hospital units or patient populations
CLABSI rate above institutional goals despite compliance with basic CLABSI prevention practices.
Some evidence suggests that use of antimicrobial CVCs may have no additional benefit in patient
care units that have already established a low incidence of catheter infections. ii. Patients have
limited venous access and a history of recurrent CLABSI. iii. Patients are at heightened risk of
severe sequelae from a CLABSI (e.g, patients with recently implanted intravascular devices, such
as a prosthetic heart valve or aortic graft).
The Arrowg+ard Blue Plus CVC is contraindicated for patients with known
hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus, and Blue FlexTip are trademarks
registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other
countries. All other trademarks are trademarks of their respective owners. MCI-100375